116 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
23 Mar 10
GTx and Ipsen expand partnership
12:00am
-looking statements
The forward-looking statements, objectives, perspectives and targets contained herein are based on the Group’s management strategy … , the perspectives, objectives or targets described in this document were prepared without taking into account external growth assumptions which may alter
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
16 Mar 20
Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
4:15pm
to have multiple data updates throughout the year. Preclinical work is also identifying additional clinical targets for our existing product candidates … with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
4 Nov 21
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
4:01pm
Conference on Molecular Targets and Cancer Therapeutics in October. The data presented showed that ONCT-534 binds to the AR-AF-1, or N-terminal … . Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Sep 06
Regulation FD Disclosure
12:00am
such statements are based.
Forward-looking statements (Ipsen)
The forward-looking statements and targets contained herein are based on Ipsen’s … -looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
10 Mar 22
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
4:15pm
on Molecular Targets showing anti-tumor activity in preclinical studies relevant to important tumor resistance mechanisms, including those involving expression … prostate cancer (mCRPC). Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently
FWP
pjqos5v07codo5s1nux
17 Nov 20
Free writing prospectus
5:27pm
8-K
EX-99.1
8agea10n
19 Nov 20
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
5:06pm
FWP
t43wj6vc5n47 zj
10 Dec 20
Free writing prospectus
12:00am
8-K
EX-99.2
4zg iocj804mts
19 Nov 20
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
5:06pm
FWP
eonge3k5dsqo1c2jrtx
27 Aug 20
Free writing prospectus
5:26pm
8-K
EX-99.2
yxxxakn
11 Dec 20
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
6:11am
8-K
EX-99.2
zq4j5
31 Aug 20
Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering
4:33pm
8-K
EX-99.1
22hvi lm0xanqikm
11 Dec 20
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
6:11am
8-K
EX-99.1
di3hi
31 Aug 20
Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering
4:33pm
FWP
7hrzy7lrq
18 Nov 20
Free writing prospectus
6:05am
FWP
r30buq
10 Dec 20
Free writing prospectus
6:11am
8-K
EX-99.1
rlyl8cwc
21 May 20
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering
4:31pm
FWP
yyv2f
27 Aug 20
Free writing prospectus
9:34pm
8-K
EX-99.1
f58hlk9s5eac0qi b6m8
21 Jul 20
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering
4:06pm